Nuage Therapeutics — Seed

CDTI Innovación disclosed a €450,000 commitment through Innvierte to Nuage Therapeutics, an IRB Barcelona and ICREA spin-out developing drugs against intrinsically disordered proteins for castration-resistant prostate cancer, co-investing with Asabys Partners' Sabadell Asabys Health Innovation Investments fund. The full size of the seed round was not disclosed in this announcement.